The Food and Drug Administration yesterday authorized the emergency use of a new over-the-counter COVID-19 antigen test. Unlike most antigen tests for at-home use, the new test does not require serial testing, FDA said. The agency expects the ACON Laboratories Flowflex COVID-19 Home Test to double the nation’s rapid at-home testing capacity over the next several weeks. The manufacturer plans to produce more than 100 million tests per month by year’s end and 200 million per month by February 2022.

In other news, Ellume on Friday recalled certain lots of its rapid at-home COVID-19 antigen test due to an increased chance of false-positive results.
 

Related News Articles

Headline
Centers for Disease Control and Prevention Director Rochelle Walensky, M.D., Friday expanded eligibility for COVID-19 booster shots to include all adults…
Headline
Texas this week filed a federal lawsuit challenging the Centers for Medicare & Medicaid Services’ interim final rule requiring COVID-19 vaccinations…
Headline
Nursing home visitation is now allowed for all residents at all times, according to updated guidance released Friday by the Centers for Medicare &…
Headline
To ensure that COVID-19 tests work as intended, the Food and Drug Administration will now enforce premarket review requirements for laboratory developed tests…
Headline
The Centers for Disease Control and Prevention will implement three new ICD-10 diagnosis codes for reporting COVID-19 vaccination status effective April 1,…
Headline
Ellume has expanded its recall of rapid at-home COVID-19 antigen tests to about 2 million tests, the Food and Drug Administration said in an update this week.…